Live Biotherapeutic Products And Microbiome CDMO Market, By Application (C.difficle, Crohns Disease, IBS and Diabetes), By Country, and By Region - Industry Analysis, Market Size, Market Share & Forecast from 2024-2032
REPORT HIGHLIGHT
Live Biotherapeutic Products And Microbiome CDMO Market size was valued at USD 29.57 Million in 2023, expanding at a CAGR of 38.20% from 2024 to 2032.
Live biotherapeutic items and microbiota. The CDMO market focuses on the creation, manufacture, and marketing of live biotherapeutic products and microbiome-based medicines. LBPs are biological products that include living organisms and improve human health by altering the microbiome. They are used to treat gastrointestinal issues, metabolic abnormalities, and infectious infections. Microbiome-based therapies use microbiota communities to improve health and treat disorders. CDMOs, or contract development and manufacturing organizations, offer specialized services to the pharmaceutical and biotechnology industries.
Live Biotherapeutic Products And Microbiome CDMO Market- Market Dynamics
- Increasing R&D Activities to Drive Market Growth
The Live Biotherapeutic Products and Microbiome CDMO Market is experiencing significant expansion due to increased research and development activities. Companies and academic institutes are spending increasingly on the development of live biotherapeutic items and microbiome-based medicines because of their potential to cure a wide range of health issues. The focus on understanding the human microbiome and its impact on health has increased R&D activities to develop novel goods and therapies. This increased research effort is driving the demand for Contract Development and Manufacturing Organizations (CDMOs) that specialize in live biotherapeutic products and microbiome-based medicines. These CDMOs play an important role in offering expertise and manufacturing skills to help these items reach the market efficiently. Collaboration between research organizations and CDMOs drives innovation and accelerates the development of novel therapeutics in this developing sector.
Live Biotherapeutic Products And Microbiome CDMO Market- Key Insights
- Our research analyst estimates that the global market will develop at a CAGR of approximately 38.20% from 2024 to 2032.
- Based on Application segmentation, the difficle Applications segment will dominate the worldwide insulin market in 2023.
- Based on region, North America was the leading revenue generator in 2023
Live Biotherapeutic Products And Microbiome CDMO Market- Segmentation Analysis:
The Global Live Biotherapeutic Products And Microbiome CDMO Market is segmented based on Application and Region.
The market is divided into five categories based on Applications: C.difficle, Crohn\'s Disease, IBS, Diabetes and Others. In 2023, the C.difficle category dominated the market. The live biotherapeutic products and microbiome market is divided into five segments based on their application: C. difficile, Crohn\'s disease, IBS, diabetes, and others. C. difficile is a bacterium prevalent in the human gut microbiome that causes severe diarrhea and colitis, especially in those who have recently taken antibiotics.
Live Biotherapeutic Products And Microbiome CDMO Market- Geographical Insights
Geographically, this market is present in North America, Latin America, Europe, Asia Pacific, and the Middle East and Africa. These zones are further split based on which countries bring business. North America dominated the global live biotherapeutic products and microbiome CDMO market in 2023, accounting for 78.0% of the total. The market is being pushed primarily by the presence of important players and increased investment in research & development activities in the region. The rising demand for effective therapies for a variety of disorders, including C. difficile, Crohn\'s disease, and IBS, has further fueled market growth in North America.
The Live Biotherapeutic Products And Microbiome CDMO market in Asia Pacific is estimated to develop at a CAGR of 44.23% over the forecast period. In recent years, the Asia Pacific market for live biotherapeutic products and microbiome CDMOs has grown significantly, with potential advances. The prevalence of IBD and Crohn\'s disease, as well as increased R&D investment and funding, are important drivers of this expansion. Furthermore, rising outsourcing and an increase in the number of clinical trials are important drivers driving Asia Pacific\'s quickest market growth.
Live Biotherapeutic Products And Microbiome CDMO Market- Competitive Landscape:
In the Live Biotherapeutic Products and Microbiome CDMO Market Competitive Landscape, several businesses are actively competing to provide services related to the development and production of live biotherapeutic products and microbiome-based medicines. Key companies in the Contract Development and Manufacturing Organization (CDMO) market include Arrant Bio, 4D Pharma, Cerbios, Biose Industrie, Assembly Biosciences, Inc., and Wacker Chemie AG. These companies specialize in providing manufacturing, formulation, and development services for live biotherapeutic products and microbiome-based treatments. Understanding the competitive environment in this sector might assist stakeholders in finding possible partners or service providers for their research and development needs.
Recent Developments:
- In December 2022, Biomica Ltd. agreed to raise USD 20 million in a funding transaction headed by Shanghai Healthcare Capital. The funding will enable the company to advance its microbiome-based medicines pipeline. Furthermore, in April 2023, the firm closed its financing round with a USD 10 million investment from Shanghai Healthcare Capital, demonstrating Biomica\'s long-term potential.
SCOPE OF THE REPORT
The scope of this report covers the market by its major segments, which include as following:
GLOBAL LIVE BIOTHERAPEUTIC PRODUCTS AND MICROBIOME CDMO MARKET KEY PLAYERS- DETAILED COMPETITIVE INSIGHTS
- Arrant Bio
- 4D Pharma
- Cerbios
- Biose Industrie
- Assembly Biosciences, Inc.
- Wacker Chemie AG
- Quay Pharmaceuticals
- NIZO
- Lonza
- Inpac Probiotics
- Others
GLOBAL LIVE BIOTHERAPEUTIC PRODUCTS AND MICROBIOME CDMO MARKET, BY APPLICATION- MARKET ANALYSIS, 2019 - 2032
- difficle
- Crohns Disease
- IBS
- Diabetes
- Others
GLOBAL LIVE BIOTHERAPEUTIC PRODUCTS AND MICROBIOME CDMO MARKET, BY REGION- MARKET ANALYSIS, 2019 - 2032
- North America
- The U.S.
- Canada
- Europe
- Germany
- France
- Italy
- Spain
- United Kingdom
- Russia
- Netherlands
- Sweden
- Poland
- Rest of Europe
- Asia Pacific
- India
- China
- South Korea
- Japan
- Australia
- Thailand
- Indonesia
- Philippines
- Rest of APAC
- Latin America
- Brazil
- Mexico
- Argentina
- Colombia
- Rest of LATAM
- The Middle East and Africa
- Saudi Arabia
- United Arab Emirates
- Israel
- Turkey
- Algeria
- Egypt
- Rest of MEA
TABLE OF CONTENT
1. Live Biotherapeutic Products And Microbiome CDMO Market Overview
1.1. Study Scope
1.2. Market Estimation Years
2. Executive Summary
2.1. Market Snippet
2.1.1. Live Biotherapeutic Products And Microbiome CDMO Market Snippet by Application
2.1.2. Live Biotherapeutic Products And Microbiome CDMO Market Snippet by Country
2.1.3. Live Biotherapeutic Products And Microbiome CDMO Market Snippet by Region
2.2. Competitive Insights
3. Live Biotherapeutic Products And Microbiome CDMO Key Market Trends
3.1. Live Biotherapeutic Products And Microbiome CDMO Market Drivers
3.1.1. Impact Analysis of Market Drivers
3.2. Live Biotherapeutic Products And Microbiome CDMO Market Restraints
3.2.1. Impact Analysis of Market Restraints
3.3. Live Biotherapeutic Products And Microbiome CDMO Market Opportunities
3.4. Live Biotherapeutic Products And Microbiome CDMO Market Future Trends
4. Live Biotherapeutic Products And Microbiome CDMO Industry Study
4.1. PEST Analysis
4.2. Porter’s Five Forces Analysis
4.3. Growth Prospect Mapping
4.4. Regulatory Framework Analysis
5. Live Biotherapeutic Products And Microbiome CDMO Market: COVID-19 Impact Analysis
5.1. Pre-COVID-19 Impact Analysis
5.2. Post-COVID-19 Impact Analysis
5.2.1. Top Performing Segments
5.2.2. Marginal Growth Segments
5.2.3. Top Looser Segments
5.2.4. Marginal Loss Segments
6. Live Biotherapeutic Products And Microbiome CDMO Market Landscape
6.1. Live Biotherapeutic Products And Microbiome CDMO Market Share Analysis, 2023
6.2. Breakdown Data, by Key Manufacturer
6.2.1. Established Players’ Analysis
6.2.2. Emerging Players’ Analysis
7. Live Biotherapeutic Products And Microbiome CDMO Market – By Application
7.1. Overview
7.1.1. Segment Share Analysis, By Application, 2023 & 2032 (%)
7.1.2. C.difficle
7.1.3. Crohns Disease
7.1.4. IBS
7.1.5. Diabetes
7.1.6. Others
8. Live Biotherapeutic Products And Microbiome CDMO Market– By Geography
8.1. Introduction
8.1.1. Segment Share Analysis, By Geography, 2023 & 2032 (%)
8.2. North America
8.2.1. Overview
8.2.2. Live Biotherapeutic Products And Microbiome CDMO Key Manufacturers in North America
8.2.3. North America Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
8.2.4. North America Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
8.2.5. U.S.
8.2.5.1. Overview
8.2.5.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
8.2.5.3. U.S. Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
8.2.6. Canada
8.2.6.1. Overview
8.2.6.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
8.2.6.3. Canada Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
8.3. Europe
8.3.1. Overview
8.3.2. Live Biotherapeutic Products And Microbiome CDMO Key Manufacturers in Europe
8.3.3. Europe Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
8.3.4. Europe Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
8.3.5. Germany
8.3.5.1. Overview
8.3.5.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
8.3.5.3. Germany Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
8.3.6. Italy
8.3.6.1. Overview
8.3.6.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
8.3.6.3. Italy Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
8.3.7. United Kingdom
8.3.7.1. Overview
8.3.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
8.3.7.3. United Kingdom Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
8.3.8. France
8.3.8.1. Overview
8.3.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
8.3.8.3. France Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
8.3.9. Russia
8.3.9.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
8.3.9.2. Russia Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
8.3.10. Netherlands
8.3.10.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
8.3.10.2. Netherlands Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
8.3.11. Sweden
8.3.11.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
8.3.11.2. Sweden Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
8.3.12. Poland
8.3.12.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
8.3.12.2. Poland Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
8.3.13. Rest of Europe
8.3.13.1. Overview
8.3.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
8.3.13.3. Rest of the Europe Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
8.4. Asia Pacific (APAC)
8.4.1. Overview
8.4.2. Live Biotherapeutic Products And Microbiome CDMO Key Manufacturers in Asia Pacific
8.4.3. Asia Pacific Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
8.4.4. Asia Pacific Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
8.4.5. India
8.4.5.1. Overview
8.4.5.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
8.4.5.3. India Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
8.4.6. China
8.4.6.1. Overview
8.4.6.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
8.4.6.3. China Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
8.4.7. Japan
8.4.7.1. Overview
8.4.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
8.4.7.3. Japan Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
8.4.8. South Korea
8.4.8.1. Overview
8.4.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
8.4.8.3. South Korea Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
8.4.9. Australia
8.4.9.1. Overview
8.4.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
8.4.9.3. Australia Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
8.4.10. Thailand
8.4.10.1. Overview
8.4.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
8.4.10.3. Thailand Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
8.4.11. Indonesia
8.4.11.1. Overview
8.4.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
8.4.11.3. Indonesia Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
8.4.12. Philippines
8.4.12.1. Overview
8.4.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
8.4.12.3. Philippines Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
8.4.13. Rest of APAC
8.4.13.1. Overview
8.4.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
8.4.13.3. Rest of APAC Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
8.5. Latin America
8.5.1. Overview
8.5.2. Live Biotherapeutic Products And Microbiome CDMO Key Manufacturers in Latin America
8.5.3. Latin America Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
8.5.4. Latin America Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
8.5.5. Brazil
8.5.5.1. Overview
8.5.5.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
8.5.5.3. Brazil Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
8.5.6. Mexico
8.5.6.1. Overview
8.5.6.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
8.5.6.3. Mexico Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
8.5.7. Argentina
8.5.7.1. Overview
8.5.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
8.5.7.3. Argentina Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
8.5.8. Colombia
8.5.8.1. Overview
8.5.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
8.5.8.3. Colombia Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
8.5.9. Rest of LATAM
8.5.9.1. Overview
8.5.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
8.5.9.3. Rest of LATAM Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
8.6. Middle East and Africa
8.6.1. Overview
8.6.2. Live Biotherapeutic Products And Microbiome CDMO Key Manufacturers in Middle East and Africa
8.6.3. Middle East and Africa Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
8.6.4. Middle East and Africa Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
8.6.5. Saudi Arabia
8.6.5.1. Overview
8.6.5.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
8.6.5.3. Saudi Arabia Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
8.6.6. United Arab Emirates
8.6.6.1. Overview
8.6.6.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
8.6.6.3. United Arab Emirates Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
8.6.7. Israel
8.6.7.1. Overview
8.6.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
8.6.7.3. Israel Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
8.6.8. Turkey
8.6.8.1. Overview
8.6.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
8.6.8.3. Turkey Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
8.6.9. Algeria
8.6.9.1. Overview
8.6.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
8.6.9.3. Algeria Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
8.6.10. Egypt
8.6.10.1. Overview
8.6.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
8.6.10.3. Egypt Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
8.6.11. Rest of MEA
8.6.11.1. Overview
8.6.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
8.6.11.3. Rest of MEA Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
9. Key Vendor Analysis- Live Biotherapeutic Products And Microbiome CDMO Industry
9.1. Competitive Dashboard
9.2. Company Profiles
9.2.1. Arrant Bio
9.2.2. 4D Pharma
9.2.3. Cerbios
9.2.4. Biose Industrie
9.2.5. Assembly Biosciences, Inc.
9.2.6. Wacker Chemie AG
9.2.7. Quay Pharmaceuticals
9.2.8. NIZO
9.2.9. Lonza
9.2.10. Inpac Probiotics
9.2.11. Others
10. 360 Degree Analyst View
11. Appendix
11.1. Research Methodology
11.2. References
11.3. Abbreviations
11.4. Disclaimer
11.5. Contact Us
